Portal de Periódicos da CAPES

Natural isoflavonoids in invasive cancer therapy: From bench to bedside

2021; Wiley; Volume: 35; Issue: 8 Linguagem: Inglês

10.1002/ptr.7072

1099-1573

Lorena Cayetano‐Salazar, Monserrat Olea‐Flores, Miriam D. Zuñiga‐Eulogio, Caroline Weinstein‐Oppenheimer, Gloria Fernández‐Tilapa, Miguel A. Mendoza‐Catalán, Ana Elvira Zacapala-Gómez, Julio Ortíz-Ortíz, Carlos Ortuño‐Pineda, Napoleón Navarro‐Tito,

Natural product bioactivities and synthesis

Cancer is a public health problem worldwide, and one of the crucial steps within tumor progression is the invasion and metastasis of cancer cells, which are directly related to cancer‐associated deaths in patients. Recognizing the molecular markers involved in invasion and metastasis is essential to find targeted therapies in cancer. Interestingly, about 50% of the discovered drugs used in chemotherapy have been obtained from natural sources such as plants, including isoflavonoids. Until now, most drugs are used in chemotherapy targeting proliferation and apoptosis‐related molecules. Here, we review recent studies about the effect of isoflavonoids on molecular targets and signaling pathways related to invasion and metastasis in cancer cell cultures, in vivo assays, and clinical trials. This review also reports that glycitein, daidzein, and genistein are the isoflavonoids most studied in preclinical and clinical trials and displayed the most anticancer activity targeting invasion‐related proteins such as MMP‐2 and MMP‐9 and also EMT‐associated proteins. Therefore, the diversity of isoflavonoids is promising molecules to be used as chemotherapeutic in invasive cancer. In the future, more clinical trials are needed to validate the effectiveness of the various natural isoflavonoids in the treatment of invasive cancer.